Return to Today's science sparks archives

2021-07-01

Figure S1. AAUC distribution by D100 post HCT.

Figure S1. AAUC distribution by D100 post HCT.
  • Stern A, Su Y, Dumke H, Fang J, Tamari R, Jakubowski A, Cho C, Giralt S, Perales MA, Papanicolaou GA

  • J Infect Dis. 2021 Apr 17. pii: 6232014. doi: 10.1093/infdis/jiab212.

2021-07-02

Fig 1. Tumor development in mice with individual and combined ablations of Brca1, Palb2, Brca2, and Trp53.

Fig 1. Tumor development in mice with individual and combined ablations of Brca1, Palb2, Brca2, and Trp53.
  • Huo Y, Selenica P, Mahdi AH, Pareja F, Kyker-Snowman K, Chen Y, Kumar R, Da Cruz Paula A, Basili T, Brown DN, Pei X, Riaz N, Tan Y, Huang YX, Li T, Barnard NJ, Reis-Filho JS, Weigelt B, Xia B

  • NPJ Breast Cancer. 2021 Apr 23;7(1):45. doi: 10.1038/s41523-021-00253-5.
Open Access button

2021-07-06

Figure 1.Case 1. The histologic section of the duodenum biopsy shows an amorphous deposit within submucosa (A), CD20 (B), and cyclin D1 (C) immunohistochemistry highlight the infiltration of MCL.

Figure 1.Case 1. The histologic section of the duodenum biopsy shows an amorphous deposit within submucosa (A), CD20 (B), and cyclin D1 (C) immunohistochemistry highlight the infiltration of MCL.
  • Yabe M, Ozkaya N, de Jong D, Aypar U, Ritorto MS, Barbe E, Miedema IHC, Sen F, Chapman JR, Landau HJ, Dogan A

  • Am J Surg Pathol. 2021 Jul 1;45(7):939-944. doi: 10.1097/PAS.0000000000001684.

2021-07-07

Fig 4. Antitumor efficacy of varying doses of S63845 combined with venetoclax.

Fig 4. Antitumor efficacy of varying doses of S63845 combined with venetoclax.
  • Bala Tannan N, Manzari MT, Herviou L, Da Silva Ferreira M, Hagen C, Kiguchi H, Manova-Todorova K, Seshan V, de Stanchina E, Heller DA, Younes A

  • Blood. 2021 Apr 15;137(15):2057-2069. doi: 10.1182/blood.2020008017.

2021-07-08

Figure 2. A, representative images of mpMRI before and after neoadjuvant therapy on patient 20.

Figure 2. A, representative images of mpMRI before and after neoadjuvant therapy on patient 20.
  • McKay RR, Xie W, Ye H, Fennessy FM, Zhang Z, Lis R, Calagua C, Rathkopf D, Laudone VP, Bubley GJ, Einstein DJ, Chang PK, Wagner AA, Parsons JK, Preston MA, Kilbridge K, Chang SL, Choudhury AD, Pomerantz MM, Trinh QD, Kibel AS, Taplin ME

  • J Urol. 2021 Jul;206(1):80-87. doi: 10.1097/JU.0000000000001702. Epub 2021 Mar 8

2021-07-09

Fig 3. Diagram of the EWSR1-SSX1 fusion. Diagrammatic representation of the chromosomal locations of the EWSR1 gene on 22q12.1 and the SSX1 gene on Xp11.23.

Fig 3. Diagram of the EWSR1-SSX1 fusion. Diagrammatic representation of the chromosomal locations of the EWSR1 gene on 22q12.1 and the SSX1 gene on Xp11.23.
  • Antonescu CR, Rosenberg AE, Xie Z, Zhang L, Perell KA, Loya AC

  • Genes Chromosomes Cancer. 2021 May 14. doi: 10.1002/gcc.22970.

2021-07-12

Fig. 1. Example of daily imaging on an MRIgRT system.

Fig. 1. Example of daily imaging on an MRIgRT system.
  • van Houdt PJ, Saeed H, Thorwarth D, Fuller CD, Hall WA, McDonald BA, Shukla-Dave A, Kooreman ES, Philippens MEP, van Lier ALHMW, Keesman R, Mahmood F, Coolens C, Stanescu T, Wang J, Tyagi N, Wetscherek A, van der Heide UA

  • Eur J Cancer. 2021 Jun 15;153:64-71. doi: 10.1016/j.ejca.2021.04.041.

2021-07-13

Fig. 3: High BRCA1 methylation levels at screening are associated with better outcomes.

Fig. 3: High BRCA1 methylation levels at screening are associated with better outcomes.
  • Swisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Aghajanian C, Konecny GE, O'Malley DM, Leary A, Provencher D, Welch S, Chen LM, Wahner Hendrickson AE, Ma L, Ghatage P, Kristeleit RS, Dorigo O, Musafer A, Kaufmann SH, Elvin JA, Lin DI, Chambers SK, Dominy E, Vo LT, Goble S, Maloney L, Giordano H, Harding T, Dobrovic A, Scott CL, Lin KK, McNeish IA

  • Nat Commun. 2021 May 3;12(1):2487. doi: 10.1038/s41467-021-22582-6.
Open Access button

2021-07-14

Graphical abstract

Graphical abstract
  • Cox N, Crozet L, Holtman IR, Loyher PL, Lazarov T, White JB, Mass E, Stanley ER, Elemento O, Glass CK, Geissmann F

  • Science. 2021 Jul 2;373(6550). pii: 373/6550/eabe9383. doi: 10.1126/science.abe9383.

2021-07-15

Fig 2. Tissue adaptation to inflammation

Fig 2. Tissue adaptation to inflammation
  • Niec RE, Rudensky AY, Fuchs E

  • Cell. 2021 Jun 24;184(13):3361-3375. doi: 10.1016/j.cell.2021.05.036.

2021-07-16

Visual Abstract

Visual Abstract
  • Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, Johnson ML, Heist RS, Patil T, Riely GJ, Jacobson JO, Yang X, Persky NS, Root DE, Lowder KE, Feng H, Zhang SS, Haigis KM, Hung YP, Sholl LM, Wolpin BM, Wiese J, Christiansen J, Lee J, Schrock AB, Lim LP, Garg K, Li M, Engstrom LD, Waters L, Lawson JD, Olson P, Lito P, Ou SI, Christensen JG, Janne PA, Aguirre AJ

  • N Engl J Med. 2021 Jun 24;384(25):2382-2393. doi: 10.1056/NEJMoa2105281.

2021-07-19

Fig. 3. IPTW Survival Curves for Premenopausal Women with Stage I LMS, by Performance of Ovarian Conservation.

Fig. 3. IPTW Survival Curves for Premenopausal Women with Stage I LMS, by Performance of Ovarian Conservation.
  • Sia TY, Huang Y, Gockley A, Melamed A, Khoury-Collado F, St Clair C, Hou JY, Tergas AI, Hershman DL, Wright JD

  • Gynecol Oncol. 2021 Jun;161(3):734-740. doi: 10.1016/j.ygyno.2021.03.027. Epub 2021 Mar 31.

2021-07-20

Fig 2. Percentage change in sums of diameters of target lesions from baseline to nadir (A) and treatment durations in ICI-pretreated patients achieving an objective response (B) by investigator assessment per irRECIST

Fig 2. Percentage change in sums of diameters of target lesions from baseline to nadir (A) and treatment durations in ICI-pretreated patients achieving an objective response (B) by investigator assessment per irRECIST
  • Lee CH, Shah AY, Rasco D, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Shaffer DR, Girones Sarrio R, Cohn AL, Vogelzang NJ, Bilen MA, Gunnestad Ribe S, Goksel M, Tennoe OK, Richards D, Sweis RF, Courtright J, Heinrich D, Jain S, Wu J, Schmidt EV, Perini RF, Kubiak P, Okpara CE, Smith AD, Motzer RJ

  • Lancet Oncol. 2021 Jul;22(7):946-958. doi: 10.1016/S1470-2045(21)00241-2. Epub 2021 Jun 15.

2021-07-21

Fig 1. TGFβ signaling pathway via SMAD- TGFβ ligand binds to transmembrane TGFβ type-II receptor (TGFβRII) and induces its phosphorylation, followed by autophosphorylation of TGFβ type-I (TGFβRI) receptor forming a heterotetrameric receptor complex with two type I receptors and two type II receptors.

Fig 1. TGFβ signaling pathway via SMAD- TGFβ ligand binds to transmembrane TGFβ type-II receptor (TGFβRII) and induces its phosphorylation, followed by autophosphorylation of TGFβ type-I (TGFβRI) receptor forming a heterotetrameric receptor complex with two type I receptors and two type II receptors.
  • Kharbanda A, Zhang L, Saha D, Tran P, Xu K, Li MO, Leung YK, Frett B, Li HY

  • Eur J Med Chem. 2021 Jun 19;223:113660. doi: 10.1016/j.ejmech.2021.113660.

2021-07-22

Fig 1. Representative NECM-forming reactions on histones.

Fig 1. Representative NECM-forming reactions on histones.
  • Faulkner S, Maksimovic I, David Y

  • Curr Opin Chem Biol. 2021 Jun 19;63:180-187. doi: 10.1016/j.cbpa.2021.05.002.

2021-07-23

Visual Abstract

Visual Abstract
  • Chen BR, Deshpande A, Barbosa K, Kleppe M, Lei X, Yeddula N, Vela PS, Campos AR, Wechsler-Reya RJ, Bagchi A, Meshinchi S, Eaves C, Jeremias I, Haferlach T, Frank DA, Ronai Z, Chanda S, Armstrong SA, Adams PD, Levine RL, Deshpande AJ

  • Blood. 2021 Jun 17;137(24):3403-3415. doi: 10.1182/blood.2020009023.

2021-07-26

Fig 1. Classic Hodgkin lymphoma, nodular sclerosis type—case 23.

Fig 1. Classic Hodgkin lymphoma, nodular sclerosis type—case 23.
  • Gru AA, Bacchi CE, Pulitzer M, Bhagat G, Kempf W, Robson A, Plaza JA, Pincus L, Raghavan S, Xu M, Vencato da Silva T, Salavaggione AL, Subtil A, Battistella M

  • J Cutan Pathol. 2021 Jun 4. doi: 10.1111/cup.14077.

2021-07-27

Graphical abstract

Graphical abstract
  • Xu S, Chaudhary O, Rodriguez-Morales P, Sun X, Chen D, Zappasodi R, Xu Z, Pinto AFM, Williams A, Schulze I, Farsakoglu Y, Varanasi SK, Low JS, Tang W, Wang H, McDonald B, Tripple V, Downes M, Evans RM, Abumrad NA, Merghoub T, Wolchok JD, Shokhirev MN, Ho PC, Witztum JL, Emu B, Cui G, Kaech SM

  • Immunity. 2021 Jul 13;54(7):1561-1577.e7. doi: 10.1016/j.immuni.2021.05.003. Epub 2021 Jun 7.

2021-07-28

Graphical abstract

Graphical abstract
  • Chow A, Schad S, Green MD, Hellmann MD, Allaj V, Ceglia N, Zago G, Shah NS, Sharma SK, Mattar M, Chan J, Rizvi H, Zhong H, Liu C, Bykov Y, Zamarin D, Shi H, Budhu S, Wohlhieter C, Uddin F, Gupta A, Khodos I, Waninger JJ, Qin A, Markowitz GJ, Mittal V, Balachandran V, Durham JN, Le DT, Zou W, Shah SP, McPherson A, Panageas K, Lewis JS, Perry JSA, de Stanchina E, Sen T, Poirier JT, Wolchok JD, Rudin CM, Merghoub T

  • Cancer Cell. 2021 Jul 12;39(7):973-988.e9. doi: 10.1016/j.ccell.2021.05.006. Epub 2021 Jun 10.

2021-07-29

Fig. 2. Pairwise single-nucleotide variant (SNV) distribution between pairs of isolates from the same collection site vs pairs of isolates from geographically distinct collection sites for both ST1 and ST2.

Fig. 2. Pairwise single-nucleotide variant (SNV) distribution between pairs of isolates from the same collection site vs pairs of isolates from geographically distinct collection sites for both ST1 and ST2.
  • Miles-Jay A, Young VB, Pamer EG, Savidge TC, Kamboj M, Garey KW, Snitkin ES

  • Microb Genom. 2021 Jun;7(6). doi: 10.1099/mgen.0.000590.
Open Access button

2021-07-30

Figure 1. Type I Inhibitor PLX9486 Binds to Mutant KITD816V With High Atomic Efficiency.

Figure 1. Type I Inhibitor PLX9486 Binds to Mutant KITD816V With High Atomic Efficiency.
  • Wagner AJ, Severson PL, Shields AF, Patnaik A, Chugh R, Tinoco G, Wu G, Nespi M, Lin J, Zhang Y, Ewing T, Habets G, Burton EA, Matusow B, Tsai J, Tsang G, Shellooe R, Carias H, Chan K, Rezaei H, Sanftner L, Marimuthu A, Spevak W, Ibrahim PN, Inokuchi K, Alcantar O, Michelson G, Tsiatis AC, Zhang C, Bollag G, Trent JC, Tap WD

  • JAMA Oncol. 2021 Jul 8. pii: 2781610. doi: 10.1001/jamaoncol.2021.2086.

2021-08-02

Figure 2. Time to the nearest PT center for (a) children and (b) adults.

Figure 2. Time to the nearest PT center for (a) children and (b) adults.
  • Maillie L, Lazarev S, Simone CB 2nd, Sisk M

  • Cancer Invest. 2021 Jul-Aug;39(6-7):582-588. doi: 10.1080/07357907.2021.1944180. Epub 2021 Jul 5.

2021-08-03

Graphical Abstract.

Graphical Abstract.
  • Lu SX, De Neef E, Thomas JD, Sabio E, Rousseau B, Gigoux M, Knorr DA, Greenbaum B, Elhanati Y, Hogg SJ, Chow A, Ghosh A, Xie A, Zamarin D, Cui D, Erickson C, Singer M, Cho H, Wang E, Lu B, Durham BH, Shah H, Chowell D, Gabel AM, Shen Y, Liu J, Jin J, Rhodes MC, Taylor RE, Molina H, Wolchok JD, Merghoub T, Diaz LA Jr, Abdel-Wahab O, Bradley RK

  • Cell. 2021 Jul 22;184(15):4032-4047.e31. doi: 10.1016/j.cell.2021.05.038. Epub 2021 Jun 24.

2021-08-04

Fig. 3. Cone beam computed tomography image blended in the treatment planning system with a display with 200 cGy isodose color-wash.

Fig. 3. Cone beam computed tomography image blended in the treatment planning system with a display with 200 cGy isodose color-wash.
  • Wang D, Chan MF, Zambri J, Lichtenwalner P, Oliver J, Gelblum D, Parikh D

  • Adv Radiat Oncol. 2021 May 28;6(5):100726. doi: 10.1016/j.adro.2021.100726. eCollection 2021 Sep-Oct.
Open Access button

2021-08-05

Graphical Abstract.

Graphical Abstract.
  • Wong HS, Park K, Gola A, Baptista AP, Miller CH, Deep D, Lou M, Boyd LF, Rudensky AY, Savage PA, Altan-Bonnet G, Tsang JS, Germain RN

  • Cell. 2021 Jul 22;184(15):3981-3997.e22. doi: 10.1016/j.cell.2021.05.028. Epub 2021 Jun 21.

2021-08-06

Figure 2. Recurrent genetic alterations in murine models of UV-associated melanomagenesis.

Figure 2. Recurrent genetic alterations in murine models of UV-associated melanomagenesis.
  • Bowman RL, Hennessey RC, Weiss TJ, Tallman DA, Crawford ER, Murphy BM, Webb A, Zhang S, La Perle KM, Burd CJ, Levine RL, Shain AH, Burd CE

  • Life Sci Alliance. 2021 Jul 1;4(9). pii: 4/9/e202101135. doi: 10.26508/lsa.202101135. Print 2021 Sep.
Open Access button

2021-08-09

Fig 1. Representative nanomaterials for CDT, including iron-based nanomaterials, organic nanomaterials and other metal-based nanomaterials.

Fig 1. Representative nanomaterials for CDT, including iron-based nanomaterials, organic nanomaterials and other metal-based nanomaterials.
  • Xin J, Deng C, Aras O, Zhou M, Wu C, An F

  • J Nanobiotechnology. 2021 Jun 28;19(1):192. doi: 10.1186/s12951-021-00936-y.
Open Access button

2021-08-11

Fig 4: CRC mortality and percent Black population map of NYC. Mortality rate is from NYC Vital Statistics 2014–2016.

Fig 4: CRC mortality and percent Black population map of NYC. Mortality rate is from NYC Vital Statistics 2014–2016.
  • Brown JJ, Asumeng CK, Greenwald D, Weissman M, Zauber A, Striplin J, Weng O, List JM, Farley SM, Winawer SJ

  • BMC Public Health. 2021 Jun 30;21(1):1280. doi: 10.1186/s12889-021-11330-6.
Open Access button

2021-08-12

Figure 1. CryoEM structure of MsmPNPase.

Figure 1. CryoEM structure of MsmPNPase.
  • Unciuleac MC, Ghosh S, de la Cruz MJ, Goldgur Y, Shuman S

  • RNA. 2021 Jun 4. pii: rna.078822.121. doi: 10.1261/rna.078822.121.

2021-08-13

Fig 1. OS, stratified by conditioning intensity. MAC, myeloablative conditioning; OS, overall survival; RIC, reduced-intensity conditioning.

Fig 1. OS, stratified by conditioning intensity. MAC, myeloablative conditioning; OS, overall survival; RIC, reduced-intensity conditioning.
  • Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolanos-Meade J

  • J Clin Oncol. 2021 Jun 20;39(18):1971-1982. doi: 10.1200/JCO.20.03502. Epub 2021 Apr 27.

2021-08-16

Fig. 1. Intratumoral vessels and satellite nodules. a Axial arterial.

Fig. 1. Intratumoral vessels and satellite nodules. a Axial arterial.
  • Arora S, Catania R, Borhani A, Horvat N, Fowler K, Harmath C

  • Abdom Radiol (NY). 2021 Aug;46(8):3686-3697. doi: 10.1007/s00261-021-03192-8. Epub 2021 Jun 30.

2021-08-17

Fig. 1 PSF does not affect Deauville scoring compared to former generation PET system.

Fig. 1 PSF does not affect Deauville scoring compared to former generation PET system.
  • Aide N, Lasnon C, Kesner A, Levin CS, Buvat I, Iagaru A, Hermann K, Badawi RD, Cherry SR, Bradley KM, McGowan DR

  • Eur J Nucl Med Mol Imaging. 2021 Jun 3. pii: 10.1007/s00259-021-05390-4. doi: 10.1007/s00259-021-05390-4.
Open Access button

2021-08-18

Fig. 2. CMTs recapitulate LQT1 disease phenotype on multiwell MEAs

Fig. 2. CMTs recapitulate LQT1 disease phenotype on multiwell MEAs
  • Giacomelli E, Sala L, Oostwaard DW, Bellin M

  • Biochem Biophys Res Commun. 2021 Aug 4;572:118-124. doi: 10.1016/j.bbrc.2021.07.068.
Open Access button

2021-08-19

Fig 2. Risk of bias assessment. This figure shows the risk of bias for each outcome.

Fig 2. Risk of bias assessment. This figure shows the risk of bias for each outcome.
  • Yang M, Li SQ, Smith CM, Zhang YL, Bao T, Mao JJ

  • Biomed Pharmacother. 2021 May 18;140:111727. doi: 10.1016/j.biopha.2021.111727.

2021-08-20

Fig 2. Duration of response from first dose of pembrolizumab

Fig 2. Duration of response from first dose of pembrolizumab
  • Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguie M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, Li H, Nam K, Kapadia E, Frenkl T, de Wit R

  • Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/S1470-2045(21)00147-9. Epub 2021 May 26.

2021-08-23

Graphical abstract

Graphical abstract
  • Satpathy S, Krug K, Jean Beltran PM, Savage SR, Petralia F, Kumar-Sinha C, Dou Y, ... Gillette MA

  • Cell. 2021 Aug 5;184(16):4348-4371.e40. doi: 10.1016/j.cell.2021.07.016.
Open Access button

2021-08-24

Fig 2. Duration of response in patients with best response

Fig 2. Duration of response in patients with best response
  • Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O'Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schecter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, Lin Y, Martin T, Jagannath S

  • Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24.

2021-08-25

Fig 7. Homeotic transformation of axial skeletons in Tasp1–/–, Gtf2a1nc/nc, and Mll1nc/nc;2nc/nc newborns.

Fig 7. Homeotic transformation of axial skeletons in Tasp1–/–, Gtf2a1nc/nc, and Mll1nc/nc;2nc/nc newborns.
  • Niizuma H, Searleman AC, Takeda S, Armstrong SA, Park CY, Cheng EH, Hsieh JJ

  • JCI Insight. 2021 Aug 9;6(15). pii: e149382. doi: 10.1172/jci.insight.149382.
Open Access button

2021-08-26

Fig 4. Rest and pharmacological stress SPECT and [18F]flurpiridaz PET images.

Fig 4. Rest and pharmacological stress SPECT and [18F]flurpiridaz PET images.
  • Mason C, Gimblet GR, Lapi SE, Lewis JS

  • Radiol Clin North Am. 2021 Sep;59(5):887-918. doi: 10.1016/j.rcl.2021.05.012.

2021-08-27

Fig 2. Percentage change in the sum of the product of diameters and maximum percent change in the standard uptake value in efficacy evaluable patients (n = 90).

Fig 2. Percentage change in the sum of the product of diameters and maximum percent change in the standard uptake value in efficacy evaluable patients (n = 90).
  • Advani R, Moskowitz AJ, Bartlett NL, Vose J, Ramchandren R, Feldman T, LaCasce AS, Christian B, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF

  • Blood. 2021 Apr 7. pii: 475691. doi: 10.1182/blood.2020009178.

2021-08-30

Fig 1. Radiomics analysis workflow using hand-crafted feature extraction along with traditional machine learning techniques and deep learning for classification and modelling.

Fig 1. Radiomics analysis workflow using hand-crafted feature extraction along with traditional machine learning techniques and deep learning for classification and modelling.
  • Bitencourt A, Daimiel Naranjo I, Lo Gullo R, Rossi Saccarelli C, Pinker K

  • Eur J Radiol. 2021 Jul 30;142:109882. doi: 10.1016/j.ejrad.2021.109882.

2021-08-31

Fig 4. TCGA molecular subtypes of muscle invasive UC by RNA expression profiling.

Fig 4. TCGA molecular subtypes of muscle invasive UC by RNA expression profiling.
  • Al-Ahmadie H, Netto GJ

  • Surg Pathol Clin. 2021 Sep;14(3):403-414. doi: 10.1016/j.path.2021.05.005.

2021-09-01

Figure 1: Representative axial computed tomography (CT) scans of common chest wall malignancies at diagnosis (white arrow).

Figure 1: Representative axial computed tomography (CT) scans of common chest wall malignancies at diagnosis (white arrow).
  • Saltsman JA, Danzer E, Hammond WJ, Rhee D, Berhe S, Monteagudo J, Price AP, Heaton TE, Jones DR, LaQuaglia MP

  • Ann Surg. 2021 Aug 1;274(2):e167-e173. doi: 10.1097/SLA.0000000000003495.

2021-09-02

Fig 3. Common challenge in data integration: Addressing partial overlap of information across cells or features.

Fig 3. Common challenge in data integration: Addressing partial overlap of information across cells or features.
  • Le Cao KA, Abadi AJ, Davis-Marcisak EF, Hsu L, Arora A, Coullomb A, Deshpande A, Feng Y, Jeganathan P, Loth M, Meng C, Mu W, Pancaldi V, Sankaran K, Singh A, Sodicoff JS, Stein-O'Brien GL, Subramanian A, Welch JD, You Y, Argelaguet R, Carey VJ, Dries R, Greene CS, Holmes S, Love MI, Ritchie ME, Yuan GC, Culhane AC, Fertig E

  • Genome Biol. 2021 Aug 5;22(1):220. doi: 10.1186/s13059-021-02433-9.
Open Access button

2021-09-03

Figure 5: Autocrine effects of mtIL-12 on Tvax cells mediate enhanced immunity of Tvax through IFN-γ.

Figure 5: Autocrine effects of mtIL-12 on Tvax cells mediate enhanced immunity of Tvax through IFN-γ.
  • Veatch JR, Singhi N, Srivastava S, Szeto JL, Jesernig B, Stull SM, Fitzgibbon M, Sarvothama M, Yechan-Gunja S, James SE, Riddell SR

  • J Clin Invest. 2021 Aug 16;131(16). pii: e144195. doi: 10.1172/JCI144195.
Open Access button

2021-09-07

Visual Abstract.

Visual Abstract.
  • Wudhikarn K, Flynn JR, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, Roshal M, Maslak PG, Geyer MB, Halton EF, Diamonte C, Davila ML, Sadelain M, Brentjens RJ, Park J

  • Blood. 2021 Apr 13. pii: 475737. doi: 10.1182/blood.2020009515.

2021-09-08

Figure 2. Life Course Framework of Biological Aging in Patients With Cancer and Cancer Survivors.

Figure 2. Life Course Framework of Biological Aging in Patients With Cancer and Cancer Survivors.
  • Mandelblatt JS, Ahles TA, Lippman ME, Isaacs C, Adams-Campbell L, Saykin AJ, Cohen HJ, Carroll J

  • JAMA Oncol. 2021 Aug 5. pii: 2782740. doi: 10.1001/jamaoncol.2021.1160.

2021-09-09

Figure 5: FANCD2 deficiency facilitates the kinetics of γH2AX foci resolution.

Figure 5: FANCD2 deficiency facilitates the kinetics of γH2AX foci resolution.
  • Deng X, Tchieu J, Higginson DS, Hsu KS, Feldman R, Studer L, Shaham S, Powell SN, Fuks Z, Kolesnick R

  • Cancer Res. 2021 May 3. pii: 0008-5472.CAN-20-3309. doi: 10.1158/0008-5472.CAN-20-3309.

2021-09-10

Figure 2. Histologic subtypes of non-hypermutant TP53-mutated endometrial carcinomas and p53 expression.

Figure 2. Histologic subtypes of non-hypermutant TP53-mutated endometrial carcinomas and p53 expression.
  • Momeni-Boroujeni A, Dahoud W, Vanderbilt CM, Chiang S, Murali R, Rios-Doria EV, Alektiar KM, Aghajanian C, Abu-Rustum NR, Ladanyi M, Ellenson LH, Weigelt B, Soslow RA

  • Clin Cancer Res. 2021 May 1;27(9):2613-2623. doi: 10.1158/1078-0432.CCR-20-4436. Epub 2021 Feb 18.

2021-09-13

Figure 6. Liver and Perihepatic Space.

Figure 6. Liver and Perihepatic Space.
  • Oliveira LRLB, Horvat N, Andrieu PIC, Panizza PSB, Cerri GG, Viana PCC

  • Br J Radiol. 2021 Sep 1;94(1125):20210091. doi: 10.1259/bjr.20210091. Epub 2021 Jul 21.

2021-09-14

Figure 1. Heat map showing correlation between different radiomics and ADC features with the two classes of lymph node (absent and present).

Figure 1. Heat map showing correlation between different radiomics and ADC features with the two classes of lymph node (absent and present).
  • Jajodia A, Gupta A, Prosch H, Mayerhoefer M, Mitra S, Pasricha S, Mehta A, Puri S, Chaturvedi A

  • Tomography. 2021 Aug 5;7(3):344-357. doi: 10.3390/tomography7030031.
Open Access button

2021-09-15

Figure 2: GSAP interacts with Fe65 to regulate APP phosphorylation and trafficking.

Figure 2: GSAP interacts with Fe65 to regulate APP phosphorylation and trafficking.
  • Xu P, Chang JC, Zhou X, Wang W, Bamkole M, Wong E, Bettayeb K, Jiang LL, Huang T, Luo W, Xu H, Nairn AC, Flajolet M, Ip NY, Li YM, Greengard P

  • J Exp Med. 2021 Aug 2;218(8). pii: 212404. doi: 10.1084/jem.20202446. Epub 2021 Jun 22.
Open Access button

2021-09-16

Fig 1. Overview of the study design and the integrated dataset.

Fig 1. Overview of the study design and the integrated dataset.
  • Schupp JC, Adams TS, Cosme C Jr, Raredon MSB, Yuan Y, Omote N, Poli S, Chioccioli M, Rose KA, Manning EP, Sauler M, DeIuliis G, Ahangari F, Neumark N, Habermann AC, Gutierrez AJ, Bui LT, Lafyatis R, Pierce RW, Meyer KB, Nawijn MC, Teichmann SA, Banovich NE, Kropski JA, Niklason LE, Pe'er D, Yan X, Homer RJ, Rosas IO, Kaminski N

  • Circulation. 2021 Jul 27;144(4):286-302. doi: 10.1161/CIRCULATIONAHA.120.052318. Epub 2021 May 25.
Open Access button